[{"Developer_Researcher":"Inovio Pharmaceuticals/Beijing Advaccine Biotechnology/VGXI Inc./ Richter-Helm BioLogics/Ology Bioservices","Product_Category":"DNA-based","Stage_of_Development":"Phase I","Product_Description":"DNA plasmid vaccine with electroporation; INO-4800"},{"Developer_Researcher":"BioNet Asia","Product_Category":"DNA-based","Stage_of_Development":"Pre-clinical","Product_Description":"DNA"},{"Developer_Researcher":"Chula Vaccine Research Center","Product_Category":"DNA-based","Stage_of_Development":"Pre-clinical","Product_Description":"DNA with electroporation"},{"Developer_Researcher":"Entos Pharmaceuticals/ Cytiva","Product_Category":"DNA-based","Stage_of_Development":"Pre-clinical","Product_Description":"DNA"},{"Developer_Researcher":"Genexine Consortium (GenNBio, International Vaccine Institute, Korea Advanced Institute of Science and Technology (KAIST), Pohang University of Science and Technology (POSTECH)/ Binex","Product_Category":"DNA-based","Stage_of_Development":"Pre-clinical","Product_Description":"DNA vaccine (GX-19)"},{"Developer_Researcher":"Immunomic Therapeutics / EpiVax / PharmaJet","Product_Category":"DNA-based","Stage_of_Development":"Pre-clinical","Product_Description":"DNA plasmid, needle-free delivery"},{"Developer_Researcher":"OPENCORONA - Cobra Biologics / Karolinska Institute","Product_Category":"DNA-based","Stage_of_Development":"Pre-clinical","Product_Description":"DNA with electroporation"},{"Developer_Researcher":"Osaka University / AnGes / Takara Bio/ Cytiva","Product_Category":"DNA-based","Stage_of_Development":"Pre-clinical","Product_Description":"DNA plasmid"},{"Developer_Researcher":"Scancell/ University of Nottingham","Product_Category":"DNA-based","Stage_of_Development":"Pre-clinical","Product_Description":"DNA"},{"Developer_Researcher":"Symvivo","Product_Category":"DNA-based","Stage_of_Development":"Pre-clinical","Product_Description":"bacTRL-Spike"},{"Developer_Researcher":"Takis/ Applied DNA Sciences/ Evvivax","Product_Category":"DNA-based","Stage_of_Development":"Pre-clinical","Product_Description":"DNA"},{"Developer_Researcher":"University of Waterloo","Product_Category":"DNA-based","Stage_of_Development":"Pre-clinical","Product_Description":"DNA"},{"Developer_Researcher":"Zydus Cadila","Product_Category":"DNA-based","Stage_of_Development":"Pre-clinical","Product_Description":"DNA plasmid"},{"Developer_Researcher":"Beijing Institute of Biological Products/ Sinopharm","Product_Category":"Inactivated virus","Stage_of_Development":"Phase II","Product_Description":"Inactivated"},{"Developer_Researcher":"Institute of Medical Biology, Chinese Academy of Medical Sciences","Product_Category":"Inactivated virus","Stage_of_Development":"Phase II","Product_Description":"Inactivated"},{"Developer_Researcher":"Sinovac/ Instituto Butantan","Product_Category":"Inactivated virus","Stage_of_Development":"Phase II","Product_Description":"CoronaVac; Inactivated (inactivated + alum); PiCoVacc"},{"Developer_Researcher":"Wuhan Institute of Biological Products/ Sinopharm","Product_Category":"Inactivated virus","Stage_of_Development":"Phase II","Product_Description":"Inactivated"},{"Developer_Researcher":"Beijing Minhai Biotechnology Co., Ltd.","Product_Category":"Inactivated virus","Stage_of_Development":"Pre-clinical","Product_Description":"Inactivated"},{"Developer_Researcher":"Osaka University / BIKEN / NIBIOHN","Product_Category":"Inactivated virus","Stage_of_Development":"Pre-clinical","Product_Description":"Inactivated"},{"Developer_Researcher":"Research Institute for Biological Safety Problems, Republic of Kazakhstan","Product_Category":"Inactivated virus","Stage_of_Development":"Pre-clinical","Product_Description":"Inactivated"},{"Developer_Researcher":"Sinovac/ Dynavax","Product_Category":"Inactivated virus","Stage_of_Development":"Pre-clinical","Product_Description":"Inactivated (inactivated + CpG 1018)"},{"Developer_Researcher":"Valneva/ Dynavax","Product_Category":"Inactivated virus","Stage_of_Development":"Pre-clinical","Product_Description":"VLA2001, Inactivated + CpG 1018"},{"Developer_Researcher":"Codagenix / Serum Institute of India","Product_Category":"Live attenuated virus","Stage_of_Development":"Pre-clinical","Product_Description":"Codon deoptimized live attenuated virus"},{"Developer_Researcher":"DZIF - German Center for Infection Research","Product_Category":"Live attenuated virus","Stage_of_Development":"Pre-clinical","Product_Description":"Live attenuated virus, measles virus (S, N targets)"},{"Developer_Researcher":"Indian Immunologicals Ltd/ Griffith University","Product_Category":"Live attenuated virus","Stage_of_Development":"Pre-clinical","Product_Description":"Codon deoptimized live attenuated virus"},{"Developer_Researcher":"CanSino Biologics/Beijing Institute of Biotechnology/ Canada's National Research Council","Product_Category":"Non-replicating viral vector","Stage_of_Development":"Phase II","Product_Description":"Non-replicating viral vector; Adenovirus Type 5 vector (Ad5-nCoV)"},{"Developer_Researcher":"Consortium of the Jenner Institute, Oxford Biomedica, University of Oxford, Vaccines Manufacturing and Innovation Centre, Pall Life Sciences, Cobra Biologics, HalixBV, Advent s.r.l., Merck KGaA, the Serum Institute, Vaccitech, and AstraZeneca","Product_Category":"Non-replicating viral vector","Stage_of_Development":"Phase II","Product_Description":"Non-replicating viral vector; AZD 1222 (formerly ChAdOx1)"},{"Developer_Researcher":"Gamaleya  Research Institute","Product_Category":"Non-replicating viral vector","Stage_of_Development":"Phase I","Product_Description":"Adeno-based"},{"Developer_Researcher":"Altimmune / University of Alabama at Birmingham","Product_Category":"Non-replicating viral vector","Stage_of_Development":"Pre-clinical","Product_Description":"AdCOVID; single-dose, intranasal vaccine; non replicating viral vector; adenovirus-based NasoVAX expressing spike protein"},{"Developer_Researcher":"Bharat Biotech/ Thomas Jefferson University","Product_Category":"Non-replicating viral vector","Stage_of_Development":"Pre-clinical","Product_Description":"Recombinant deactivated rabies virus containing S1"},{"Developer_Researcher":"Centro Nacional Biotecnologia (CNB-CSIC), Spain","Product_Category":"Non-replicating viral vector","Stage_of_Development":"Pre-clinical","Product_Description":"Non-replicating viral vector, MVA expressing structural proteins"},{"Developer_Researcher":"DZIF - German Center for Infection Research","Product_Category":"Non-replicating viral vector","Stage_of_Development":"Pre-clinical","Product_Description":"Non-replicating viral vector; MVA-S encoded"},{"Developer_Researcher":"GeoVax / BravoVax","Product_Category":"Non-replicating viral vector","Stage_of_Development":"Pre-clinical","Product_Description":"Non-replicating viral vector; MVA encoded VLP"},{"Developer_Researcher":"Greffex","Product_Category":"Non-replicating viral vector","Stage_of_Development":"Pre-clinical","Product_Description":"Non-replicating viral vector; Ad5 S (GREVAX™ platform)"},{"Developer_Researcher":"Grousbeck Gene Therapy Center at Mass. Eye and Ear/ AveXis, a Novartis Company/  Viralgen/ Aldevron/ Catalent/ Penn Medicine","Product_Category":"Non-replicating viral vector","Stage_of_Development":"Pre-clinical","Product_Description":"AAVCOVID, Adeno-associated viral vector (AAV), spike protein"},{"Developer_Researcher":"IDIBAPS- Hospital Clinic, Spain","Product_Category":"Non-replicating viral vector","Stage_of_Development":"Pre-clinical","Product_Description":"MVA-S"},{"Developer_Researcher":"ImmunityBio/ NantKwest","Product_Category":"Non-replicating viral vector","Stage_of_Development":"Pre-clinical","Product_Description":"Non-replicating viral vector; [E1-, E2b-, E3-] hAd5-COVID19-Spike/Nucleocapsid"},{"Developer_Researcher":"Janssen Pharmaceutical Companies/ Beth Israel Deaconess Medical Center/ Emergent BioSolutions/ Catalent","Product_Category":"Non-replicating viral vector","Stage_of_Development":"Pre-clinical","Product_Description":"Ad26.COV2-S, Non replicating viral vector; Ad26 (alone or with MVA boost)"},{"Developer_Researcher":"National Center for Genetic Engineering and Biotechnology (BIOTEC)/ GPO, Thailand","Product_Category":"Non-replicating viral vector","Stage_of_Development":"Pre-clinical","Product_Description":"Inactivated Flu-based SARS-CoV2 vaccine + Adjuvant"},{"Developer_Researcher":"ReiThera/ Leukocare/ Univercells","Product_Category":"Non-replicating viral vector","Stage_of_Development":"Pre-clinical","Product_Description":"Non-replicating viral vector; replication defective simian adenovirus (GRAd) encoding SARS-CoV-2 S"},{"Developer_Researcher":"Stabilitech Biopharma Ltd","Product_Category":"Non-replicating viral vector","Stage_of_Development":"Pre-clinical","Product_Description":"Oral Ad5 S"},{"Developer_Researcher":"University of Georgia/ University of Iowa","Product_Category":"Non-replicating viral vector","Stage_of_Development":"Pre-clinical","Product_Description":"Non-replicating viral vector; parainfluenza virus 5 (PIV5)-based vaccine expressing the spike protein"},{"Developer_Researcher":"University of Manitoba","Product_Category":"Non-replicating viral vector","Stage_of_Development":"Pre-clinical","Product_Description":"Non-replicating viral vector; dendritic cell-based vaccine"},{"Developer_Researcher":"Valo Therapeutics Ltd","Product_Category":"Non-replicating viral vector","Stage_of_Development":"Pre-clinical","Product_Description":"Adenovirus-based + HLA-matched peptides (Pan-Corona)"},{"Developer_Researcher":"Vaxart / Emergent BioSolutions","Product_Category":"Non-replicating viral vector","Stage_of_Development":"Pre-clinical","Product_Description":"Non-replicating viral vector; Oral Vaccine\n platform"},{"Developer_Researcher":"Clover Biopharmaceuticals Inc. / GSK / Dynavax","Product_Category":"Protein subunit","Stage_of_Development":"Phase I","Product_Description":"Protein subunit, native like trimeric subunit spike protein"},{"Developer_Researcher":"Novavax/ Emergent BioSolutions/ Praha Vaccines/Serum Institute of India/ AGC Biologics","Product_Category":"Protein subunit","Stage_of_Development":"Phase I","Product_Description":"Protein subunit; NVX-CoV2373; Full-length recombinant SARS COV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M"},{"Developer_Researcher":"AJ Vaccines","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Protein subunit; S protein"},{"Developer_Researcher":"Anhui Zhifei Longcom Biopharmaceutical/ Institute of Microbiology, Chinese Academy of Sciences","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Adjuvanted recombinant protein (RBD-Dimer)"},{"Developer_Researcher":"AnyGo Technology","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Protein subunit, recombinant S1-Fc fusion protein"},{"Developer_Researcher":"Applied Biotechnology Institute, Inc.","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Orally delivered, heat stable subunit"},{"Developer_Researcher":"Axon Neuroscience SE","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Peptides derived from Spike protein"},{"Developer_Researcher":"Baiya Phytopharm/ Chula Vaccine Research Center","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Plant-based subunit (RBD-Fc + Adjuvant)"},{"Developer_Researcher":"Baylor College of Medicine","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Protein subunit; S1 or RBD protein"},{"Developer_Researcher":"Biological E Ltd","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Protein subunit; adjuvanted protein subunit (RBD)"},{"Developer_Researcher":"BiOMVis Srl/ University of Trento","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"OMV-based vaccine"},{"Developer_Researcher":"Chulalongkorn University/ GPO, Thailand","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"RBD protein fused with Fc of IgG + Adjuvant"},{"Developer_Researcher":"EpiVax","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Protein subunit EPV-CoV-19"},{"Developer_Researcher":"EpiVax / University of Georgia","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Protein subunit; S protein"},{"Developer_Researcher":"ExpreS2ion","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Protein subunit, drosophila S2 insect cell expression system VLPs"},{"Developer_Researcher":"FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Protein subunit; peptide vaccine"},{"Developer_Researcher":"FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Protein subunit; subunit vaccine"},{"Developer_Researcher":"Flow Pharma","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Protein subunit, peptide"},{"Developer_Researcher":"Generex / EpiVax","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Protein subunit; Ii-Key peptide"},{"Developer_Researcher":"Heat Biologics (Zolovax)/ University of Miami/ Waisman Biomanufacturing","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Protein subunit (gp-96 backbone)"},{"Developer_Researcher":"iBio / CC-Pharming","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Protein subunit; Subunit protein, plant produced"},{"Developer_Researcher":"ImmunoPrecise","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Spike-based (epitope screening)"},{"Developer_Researcher":"IMV, Inc., Canadian Center for Vaccinology at Dalhousie University, Izaak Walton Killam Health Center, Nova Scotia Health Authority, Canadian Immunization Research Network, University of Laval, Global Urgent and Advanced Research and Development in Canada","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Protein subunit; DPX-COVID-19, protein subunit, peptide antigens formulated in LNP"},{"Developer_Researcher":"Innovax / Xiamen University / GSK","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Protein subunit; COVID-19 XWG-03 truncated Spike proteins"},{"Developer_Researcher":"Intravacc/Epivax","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Outer Membrane Vesicle (OMV)-peptide"},{"Developer_Researcher":"Intravacc/Epivax","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Outer Membrane Vesicle (OMV)-subunit"},{"Developer_Researcher":"Kentucky BioProcessing (British American Tobacco)","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"RBD-based"},{"Developer_Researcher":"LakePharma, Inc.","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Protein subunit, nanoparticle vaccine"},{"Developer_Researcher":"Lomonosov Moscow State University","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Structurally modified spherical particles of the tobacco mosaic virus (TMV)"},{"Developer_Researcher":"Max-Planck Institute of Colloids and Interfaces","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Targeted (Langerhans cell specific) protein subunit; spike based"},{"Developer_Researcher":"Medigen Vaccine Biologics Corp/ NIAID/ Dynavax","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"S-2 P protein + CpG 1018"},{"Developer_Researcher":"MIGAL Galilee Research Institute","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Protein subunit; oral E. coli-based protein expression system of S and N proteins"},{"Developer_Researcher":"MOGAM Institute for Biomedical Research, GC Pharma","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Protein subunit"},{"Developer_Researcher":"National Institute of Infectious Disease, Japan","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Protein subunit, S protein + adjuvant"},{"Developer_Researcher":"Neovii/Tel Aviv University","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"RBD-based"},{"Developer_Researcher":"OncoGen","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Protein subunit, synthetic long peptide vaccine candidate for S and M proteins"},{"Developer_Researcher":"Osaka University / BIKEN / National Institutes of Biomedical Innovation, Japan","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Protein subunit, VLP-recombinant protein + adjuvant"},{"Developer_Researcher":"PDS Biotechnology","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"PDS-0203; Versamune T-cell activating technology"},{"Developer_Researcher":"PREVENT-nCoV consortium (AdaptVac, Institute for Tropical Medicine at University of Tubingen, Leiden University Medical Center, University of Copenhagen, ExpreS2ion Biotechnologies, Wageningen University)/ Bavarian Nordic","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Protein subunit, capsid-like particle (CLP)"},{"Developer_Researcher":"Quadram Institute Biosciences","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"OMV-based vaccine"},{"Developer_Researcher":"Sanofi Pasteur / GSK","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Protein subunit; S protein, baculovirus production"},{"Developer_Researcher":"St. Petersburg Scientific Research Institute of Vaccines and Serums","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Protein subunit, recombinant protein, nanoparticles (based on S-protein and other epitopes)"},{"Developer_Researcher":"UMN Pharma (Shionogi)","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Protein subunit; recombinant protein vaccine, utilizing baculovirus expression vector system technology"},{"Developer_Researcher":"University of Alberta","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Protein subunit; spike based"},{"Developer_Researcher":"University of California, San Diego","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Protein subunit; plant virus nanotechnology formulated as injectable and microneedle patch"},{"Developer_Researcher":"University of Cambridge / DIOSynVax","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Protein subunit; S protein"},{"Developer_Researcher":"University of Pittsburgh","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"PittCoVacc, Protein subunit, microneedle arrays S1 subunit"},{"Developer_Researcher":"University of Queensland / GSK / Dynavax/ CSL","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Protein subunit; molecular clamp stabilized Spike protein"},{"Developer_Researcher":"University of San Martin and CONICET, Argentina","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Protein subunit"},{"Developer_Researcher":"Vabiotech","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Protein subunit, recombinant S protein in IC-BEVS"},{"Developer_Researcher":"Vaxil Bio","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Protein subunit; peptide"},{"Developer_Researcher":"Vaxine Pty Ltd / Flinders University / Oracle","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Protein subunit; recombinant spike protein with Advax adjuvant"},{"Developer_Researcher":"Verndari/ University of California, Davis","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Spike protein; VaxiPatch microneedle array dermal patch"},{"Developer_Researcher":"VIDO-InterVac, University of Saskatchewan","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Protein subunit, adjuvanted microsphere peptide"},{"Developer_Researcher":"WRAIR / USAMRIID","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Protein subunit; S protein"},{"Developer_Researcher":"Yisheng Biopharma","Product_Category":"Protein subunit","Stage_of_Development":"Pre-clinical","Product_Description":"Protein subunit, recombinant protein"},{"Developer_Researcher":"BIOCAD / IEM","Product_Category":"Replicating viral vector","Stage_of_Development":"Pre-clinical","Product_Description":"Replicating viral vector, live viral vectored vaccine based on attenuated influenza virus backbone (intranasal)"},{"Developer_Researcher":"FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo","Product_Category":"Replicating viral vector","Stage_of_Development":"Pre-clinical","Product_Description":"Replicating viral vector; measles vector"},{"Developer_Researcher":"FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo","Product_Category":"Replicating viral vector","Stage_of_Development":"Pre-clinical","Product_Description":"Replicating viral vector; VSV vector"},{"Developer_Researcher":"FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo","Product_Category":"Replicating viral vector","Stage_of_Development":"Pre-clinical","Product_Description":"Replicating viral vector, recombinant vaccine based on Influenza A virus, for the prevention of COVID-19 (intranasal)"},{"Developer_Researcher":"Fundacao Oswaldo Cruz and Instituto Buntantan","Product_Category":"Replicating viral vector","Stage_of_Development":"Pre-clinical","Product_Description":"Attenuated Influenza expressing an antigenic portion of the Spike protein"},{"Developer_Researcher":"IAVI/ Merck","Product_Category":"Replicating viral vector","Stage_of_Development":"Pre-clinical","Product_Description":"Replicating viral vector, replication-competent VSV chimeric virus technology (VSVdeltaG) delivering the SARS-CoV-2 Spike (S) glycoprotein"},{"Developer_Researcher":"Institut Pasteur / Themis / University of Pittsburgh / Merck","Product_Category":"Replicating viral vector","Stage_of_Development":"Pre-clinical","Product_Description":"Replicating viral vector; measles vector"},{"Developer_Researcher":"Intravacc/ Wageningen Bioveterinary Research/Utrecht Univ.","Product_Category":"Replicating viral vector","Stage_of_Development":"Pre-clinical","Product_Description":"Newcastle disease virus vector (NDV-SARS-CoV-2/Spike)"},{"Developer_Researcher":"Israel\n  Institute for Biological Research/ Weizmann Institute of Science","Product_Category":"Replicating viral vector","Stage_of_Development":"Pre-clinical","Product_Description":"VSV-S"},{"Developer_Researcher":"KU Leuven","Product_Category":"Replicating viral vector","Stage_of_Development":"Pre-clinical","Product_Description":"Replicating viral vector; YF17D Vector"},{"Developer_Researcher":"The Lancaster University, UK","Product_Category":"Replicating viral vector","Stage_of_Development":"Pre-clinical","Product_Description":"Avian paramyxovirus vector (APMV)"},{"Developer_Researcher":"The University of Hong Kong","Product_Category":"Replicating viral vector","Stage_of_Development":"Pre-clinical","Product_Description":"Replicating viral vector, influenza vector expressing RBD"},{"Developer_Researcher":"Tonix Pharma / Southern Research","Product_Category":"Replicating viral vector","Stage_of_Development":"Pre-clinical","Product_Description":"Replicating viral vector; horsepox vector expressing S protein; TNX-1800"},{"Developer_Researcher":"University of Western Ontario","Product_Category":"Replicating viral vector","Stage_of_Development":"Pre-clinical","Product_Description":"Replicating viral vector; VSV-S"},{"Developer_Researcher":"University of Wisconsin-Madison / FluGen/ Bharat Biotech","Product_Category":"Replicating viral vector","Stage_of_Development":"Pre-clinical","Product_Description":"M2-deficient single replication (M2SR) influenza vector"},{"Developer_Researcher":"Zydus Cadila","Product_Category":"Replicating viral vector","Stage_of_Development":"Pre-clinical","Product_Description":"Replicating viral vector; measles vector"},{"Developer_Researcher":"Moderna/ NIAID/ Lonza","Product_Category":"RNA-based vaccine","Stage_of_Development":"Phase II","Product_Description":"RNA; LNP-encapsulated mRNA (mRNA 1273)"},{"Developer_Researcher":"BioNTech/ Fosun Pharma/ Pfizer","Product_Category":"RNA-based vaccine","Stage_of_Development":"Phase I","Product_Description":"3 LNP-mRNAs; BNT162"},{"Developer_Researcher":"Imperial College London/ VacEquity Global Health","Product_Category":"RNA-based vaccine","Stage_of_Development":"Phase I","Product_Description":"RNA; LNP-nCoVsaRNA"},{"Developer_Researcher":"Arcturus/Duke-NUS/ Catalent","Product_Category":"RNA-based vaccine","Stage_of_Development":"Pre-clinical","Product_Description":"LUNAR-COV19; RNA; mRNA"},{"Developer_Researcher":"BIOCAD","Product_Category":"RNA-based vaccine","Stage_of_Development":"Pre-clinical","Product_Description":"RNA; liposome-encapsulated mRNA"},{"Developer_Researcher":"CanSino Biologics/Precision Nanosystems","Product_Category":"RNA-based vaccine","Stage_of_Development":"Pre-clinical","Product_Description":"RNA; mRNA lipid nanoparticle (mRNA-LNP)"},{"Developer_Researcher":"Centro Nacional Biotecnologia (CNB-CSIC), Spain","Product_Category":"RNA-based vaccine","Stage_of_Development":"Pre-clinical","Product_Description":"RNA; Replicating defective SARS-CoV-2 derived RNAs"},{"Developer_Researcher":"Chimeron Bio/ George Mason University's National Center for Biodefense and Infectious  Disease","Product_Category":"RNA-based vaccine","Stage_of_Development":"Pre-clinical","Product_Description":"Self amplifying RNA, self-assembling delivery system"},{"Developer_Researcher":"China CDC / Tongji University / Stermina","Product_Category":"RNA-based vaccine","Stage_of_Development":"Pre-clinical","Product_Description":"RNA; mRNA"},{"Developer_Researcher":"Chula Vaccine Research Center/University of Pennsylvania","Product_Category":"RNA-based vaccine","Stage_of_Development":"Pre-clinical","Product_Description":"LNP-mRNA"},{"Developer_Researcher":"CureVac","Product_Category":"RNA-based vaccine","Stage_of_Development":"Pre-clinical","Product_Description":"RNA; mRNA"},{"Developer_Researcher":"eTheRNA Immunotherapies / EpiVax/ Nexelis/ REPROCELL / Centre for the Evaluation of Vaccination of the University of Antwerp","Product_Category":"RNA-based vaccine","Stage_of_Development":"Pre-clinical","Product_Description":"RNA; mRNA in an intranasal delivery system (cross-strain protective COV-2 mRNA) vaccine for high-risk populations"},{"Developer_Researcher":"FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo","Product_Category":"RNA-based vaccine","Stage_of_Development":"Pre-clinical","Product_Description":"RNA; mRNA"},{"Developer_Researcher":"Fudan University / Shanghai JiaoTong University / RNACure Biopharma","Product_Category":"RNA-based vaccine","Stage_of_Development":"Pre-clinical","Product_Description":"RNA; LNP-encapsulated mRNA cocktail encoding VLP"},{"Developer_Researcher":"Fudan University / Shanghai JiaoTong University / RNACure Biopharma","Product_Category":"RNA-based vaccine","Stage_of_Development":"Pre-clinical","Product_Description":"RNA; LNP-encapsulated mRNA cocktail encoding RBD"},{"Developer_Researcher":"GeneOne Life Science / Houston Methodist","Product_Category":"RNA-based vaccine","Stage_of_Development":"Pre-clinical","Product_Description":"RNA"},{"Developer_Researcher":"Greenlight Biosciences","Product_Category":"RNA-based vaccine","Stage_of_Development":"Pre-clinical","Product_Description":"mRNA"},{"Developer_Researcher":"IDIBAPS- Hospital Clinic, Spain","Product_Category":"RNA-based vaccine","Stage_of_Development":"Pre-clinical","Product_Description":"mRNA"},{"Developer_Researcher":"Max Planck Institute of Colloids and Interfaces","Product_Category":"RNA-based vaccine","Stage_of_Development":"Pre-clinical","Product_Description":"mRNA in targeted LPNs (Langerhans cell specific)"},{"Developer_Researcher":"RNAimmune, Inc.","Product_Category":"RNA-based vaccine","Stage_of_Development":"Pre-clinical","Product_Description":"RNA; several mRNA candidates"},{"Developer_Researcher":"Sanofi Pasteur / Translate Bio","Product_Category":"RNA-based vaccine","Stage_of_Development":"Pre-clinical","Product_Description":"LNP-mRNA"},{"Developer_Researcher":"University of Tokyo / Daiichi-Sankyo","Product_Category":"RNA-based vaccine","Stage_of_Development":"Pre-clinical","Product_Description":"RNA; LNP-encapsulated mRNA"},{"Developer_Researcher":"Ziphius Therapeutics/ Ghent University","Product_Category":"RNA-based vaccine","Stage_of_Development":"Pre-clinical","Product_Description":"RNA; ZIP-1642, vaccine consists of a combination of mRNA molecules, encoding multiple SARS-CoV-2 antigens"},{"Developer_Researcher":"ARTES Biotechnology","Product_Category":"Virus-like particle","Stage_of_Development":"Pre-clinical","Product_Description":"VLP; eVLP"},{"Developer_Researcher":"Doherty Institute","Product_Category":"Virus-like particle","Stage_of_Development":"Pre-clinical","Product_Description":"VLP"},{"Developer_Researcher":"Imophoron Ltd / Bristol University's Max Planck Centre","Product_Category":"Virus-like particle","Stage_of_Development":"Pre-clinical","Product_Description":"VLP; ADDomerTM multiepitope display"},{"Developer_Researcher":"IrsiCaixa AIDS Research/ IRTA-CReSA/ Barcelona Supercomputing Centre/ Grifols","Product_Category":"Virus-like particle","Stage_of_Development":"Pre-clinical","Product_Description":"S protein integrated in HIV VLPs"},{"Developer_Researcher":"Mahidol University/ The Government Pharmaceutical Organization (GPO)","Product_Category":"Virus-like particle","Stage_of_Development":"Pre-clinical","Product_Description":"VLP + Adjuvant"},{"Developer_Researcher":"Medicago Inc.","Product_Category":"Virus-like particle","Stage_of_Development":"Pre-clinical","Product_Description":"VLP; plant-derived VLP"},{"Developer_Researcher":"Navarrabiomed, Oncoimmunology group","Product_Category":"Virus-like particle","Stage_of_Development":"Pre-clinical","Product_Description":"Virus-like particles, lentivirus, and baculovirus vehicles"},{"Developer_Researcher":"OSIVAX","Product_Category":"Virus-like particle","Stage_of_Development":"Pre-clinical","Product_Description":"VLP (COVID-19 and SARS1)"},{"Developer_Researcher":"Saiba GmbH","Product_Category":"Virus-like particle","Stage_of_Development":"Pre-clinical","Product_Description":"VLP; virus-like particle, based on RBD displayed on virus-like particle"},{"Developer_Researcher":"University of Sao Paulo","Product_Category":"Virus-like particle","Stage_of_Development":"Pre-clinical","Product_Description":"VLPs peptides/whole virus"},{"Developer_Researcher":"VBI Vaccines / National Research Council of Canada","Product_Category":"Virus-like particle","Stage_of_Development":"Pre-clinical","Product_Description":"Enveloped virus-like particle (eVLP): Pan-coronavirus vaccine candidate, targeting COVID-19, SARS, and MERS, spike protein"},{"Developer_Researcher":"AbVision","Product_Category":"Unknown","Stage_of_Development":"Pre-clinical","Product_Description":"AVI-205"},{"Developer_Researcher":"Catholic University/ Millennium Institute of Immunology and Immunotherapy/ Technological Consortium in Clinical Molecular Biomedicine, Chile","Product_Category":"Unknown","Stage_of_Development":"Pre-clinical","Product_Description":"Unknown"},{"Developer_Researcher":"Codiak BioSciences/ Ragon Institute","Product_Category":"Unknown","Stage_of_Development":"Pre-clinical","Product_Description":"exoVACC exome platform"},{"Developer_Researcher":"Covaxx","Product_Category":"Unknown","Stage_of_Development":"Pre-clinical","Product_Description":"Unknown"},{"Developer_Researcher":"Emergex Vaccines/ George Mason University's National Center for Biodefense and Infectious Diseases (NCBID)","Product_Category":"Unknown","Stage_of_Development":"Pre-clinical","Product_Description":"Unknown"},{"Developer_Researcher":"Genomics Research Hub of Helix Biogen Consult in Ogbomoso, Nigeria/ Elizade University, Ondo State, Federal Medical Centre, Ido, Ekiti State/ Massasoit Community College/ Ladoke Akintola University of Technology, Ogbomoso, Adeleke University, Ede","Product_Category":"Unknown","Stage_of_Development":"Pre-clinical","Product_Description":"Unknown"},{"Developer_Researcher":"HaloVax (Voltron Therapeutics) / The Vaccine & Immunotherapy Center at the Massachusetts General Hospital","Product_Category":"Unknown","Stage_of_Development":"Pre-clinical","Product_Description":"Self-assembling vaccine (fusion protein of a heat shock protein and Avidin, with biotinylated immunogenic peptides)"},{"Developer_Researcher":"ISR Immune System Regulation","Product_Category":"Unknown","Stage_of_Development":"Pre-clinical","Product_Description":"ISR-50"},{"Developer_Researcher":"NidoVax","Product_Category":"Unknown","Stage_of_Development":"Pre-clinical","Product_Description":"unknown; IMT504 technology"},{"Developer_Researcher":"Oragenics (Noachis Terra)/ Aragen Bioscience","Product_Category":"Unknown","Stage_of_Development":"Pre-clinical","Product_Description":"TerraCoV2"},{"Developer_Researcher":"Precision Vaccines Program at Boston Children's Hospital","Product_Category":"Unknown","Stage_of_Development":"Pre-clinical","Product_Description":"Unknown"},{"Developer_Researcher":"Shenzhen Geno-Immune Medical Institute","Product_Category":"Unknown","Stage_of_Development":"Pre-clinical","Product_Description":"Artificial antigen-presenting cells modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins"},{"Developer_Researcher":"Shenzhen Geno-Immune Medical Institute","Product_Category":"Unknown","Stage_of_Development":"Pre-clinical","Product_Description":"LV-SMENP-DC Dendritic cells modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins; administered with antigen-specific cytotoxic T lymphocytes"},{"Developer_Researcher":"SK Biosciences","Product_Category":"Unknown","Stage_of_Development":"Pre-clinical","Product_Description":"Unknown"},{"Developer_Researcher":"SmartPharm Therapeutics / Sorrento Therapeutics","Product_Category":"Unknown","Stage_of_Development":"Pre-clinical","Product_Description":"Gene-encoded antibody vaccine, non-viral nanoparticle delivery"},{"Developer_Researcher":"Tulane University","Product_Category":"Unknown","Stage_of_Development":"Pre-clinical","Product_Description":"Unknown"},{"Developer_Researcher":"Universite Laval","Product_Category":"Unknown","Stage_of_Development":"Pre-clinical","Product_Description":"Unknown"},{"Developer_Researcher":"Vault Pharma/ University of California Los Angeles","Product_Category":"Unknown","Stage_of_Development":"Pre-clinical","Product_Description":"nanoparticles (vaults) as second-line defense of infection"},{"Developer_Researcher":"Vir Biotechnology / GSK","Product_Category":"Unknown","Stage_of_Development":"Pre-clinical","Product_Description":"Unknown"},{"Developer_Researcher":"Vivaldi Biosciences/ Esco Aster Pte Ltd","Product_Category":"Unknown","Stage_of_Development":"Pre-clinical","Product_Description":"Chimeric vaccine (coronavirus and influenza)"},{"Developer_Researcher":"University of California, Los Angeles (Horwitz Lab)","Product_Category":"Replicating bacterial vector","Stage_of_Development":"Pre-clinical","Product_Description":"Recombinant LVS ΔcapB – vectored vaccine expressing multiple SARS-CoV-2 antigens"}]